AZ1495

AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC50 values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a Kd value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) [1].

Product Specifications

CAS Number

[2196204-23-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IRAK

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AZ1495.html

Purity

98.07

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

C1(C(C2CCOCC2)=CN3)=C3N=CN=C1N[C@@H]4CC[C@@H](N5CCOCC5)CC4

Molecular Formula

C21H31N5O2

Molecular Weight

385.50

Precautions

H302, H315, H319, H335

References & Citations

[1]Scott JS, et al. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma. J Med Chem. 2017 Dec 28;60 (24) :10071-10091.